// App-Quantinova.ai

PB1271 : Pharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etexilate in Paediatric Patients with Venous Thromboembolism

Researchers

Presenter

  • D. Roeshammar

Principal Investigators

  • F. Huang

  • M. Albisetti

  • L. Bomgaars

  • E. Chalmers

  • M. Luciani

  • J. Halton

  • L. Mitchell

  • D. Joseph

  • I. Tartakovsky

  • S. Gropper

  • P. Reilly

  • M. Brueckmann

  • L. Brandao

Medical Centers

  • Pharmetheus,Uppsala,Sweden

  • Boehringer Ingelheim Pharmaceuticals, Inc, Translational Medicine and Clinical Pharmacology, Ridgefield, United States

  • University Children's Hospital, Hematology Department, Zürich, Switzerland

  • Texas Children's Cancer Center, Baylor College of Medicine, Department of Pediatrics, Houston, United States

  • Royal Hospital for Sick Children, Glasgow, United Kingdom

  • Pediatric Hospital Bambino Gesù, Pediatric Hematology/Oncology, Rome, Italy

  • University of Ottawa, Children's Hospital of Eastern Ontario, Ontario, Ontario, Canada

  • Boehringer Ingelheim International GmbH, Therapeutic Area Cardiovascular Medicine, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim International GmbH, Therapeutic Area Cardiovascular Medicine, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim Pharmaceuticals, Inc., Therapeutic Area Cardiovascular Medicine, Ridgefield, United States

  • University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada

Locations

  • Sweden

  • United States

  • Switzerland

  • United Kingdom

  • Italy

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Pradax

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved